PPARD and obesity due to melanocortin 4 receptor deficiency: While there are currently no PPARδ agonists in clinical use, promising studies in animals have demonstrated that activating PPARδ has beneficial effects on obesity, hypercholesterolemia, insulin resistance, and exercise endurance (20, 21).